Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT552… Read more
Market Cap & Net Worth: Bicycle Therapeutics Ltd (BCYC)
Bicycle Therapeutics Ltd (NASDAQ:BCYC) has a market capitalization of $253.14 Million ($253.14 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28718 globally and #9554 in its home market, demonstrating a -5.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bicycle Therapeutics Ltd's stock price $5.07 by its total outstanding shares 49929952 (49.93 Million).
Bicycle Therapeutics Ltd Market Cap History: 2019 to 2026
Bicycle Therapeutics Ltd's market capitalization history from 2019 to 2026. Data shows change from $470.84 Million to $253.14 Million (-11.86% CAGR).
Index Memberships
Bicycle Therapeutics Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #744 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2386 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.00% | #248 of 263 |
Weight: Bicycle Therapeutics Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bicycle Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bicycle Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
19.82x
Bicycle Therapeutics Ltd's market cap is 19.82 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $470.84 Million | $13.80 Million | -$30.61 Million | 34.12x | N/A |
| 2020 | $896.24 Million | $10.39 Million | -$51.01 Million | 86.26x | N/A |
| 2021 | $3.04 Billion | $11.70 Million | -$66.82 Million | 259.83x | N/A |
| 2022 | $1.48 Billion | $14.46 Million | -$112.72 Million | 102.19x | N/A |
| 2023 | $902.73 Million | $26.98 Million | -$180.66 Million | 33.46x | N/A |
| 2024 | $699.02 Million | $35.27 Million | -$169.03 Million | 19.82x | N/A |
Competitor Companies of BCYC by Market Capitalization
Companies near Bicycle Therapeutics Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Bicycle Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Bicycle Therapeutics Ltd Historical Marketcap From 2019 to 2026
Between 2019 and today, Bicycle Therapeutics Ltd's market cap moved from $470.84 Million to $ 253.14 Million, with a yearly change of -11.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $253.14 Million | -28.39% |
| 2025 | $353.50 Million | -49.43% |
| 2024 | $699.02 Million | -22.57% |
| 2023 | $902.73 Million | -38.92% |
| 2022 | $1.48 Billion | -51.37% |
| 2021 | $3.04 Billion | +239.11% |
| 2020 | $896.24 Million | +90.35% |
| 2019 | $470.84 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Bicycle Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $253.14 Million USD |
| MoneyControl | $253.14 Million USD |
| MarketWatch | $253.14 Million USD |
| marketcap.company | $253.14 Million USD |
| Reuters | $253.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.